Cardioprotection in female rats subjected to chronic volume overload: Synergistic interaction of estrogen and phytoestrogens

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 1, 2008, Pages

  Gardner, Jason D ^a,b   Brower, Gregory L ^a   Voloshenyuk, Tetyana G ^a   Janicki, Joseph S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Diet; Fistula; Heart failure; Hormones; Hypertrophy; Physiology; Remodeling

Indexed keywords

ESTROGEN; PHYTOESTROGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VOLUME; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE COMPLIANCE; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART PROTECTION; HEART SIZE; HEART VENTRICLE REMODELING; HORMONAL REGULATION; HORMONE ACTION; HYPERVOLEMIA; LUNG EDEMA; NONHUMAN; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANIMALS; AORTA, ABDOMINAL; ARTERIOVENOUS SHUNT, SURGICAL; CARDIAC OUTPUT; CARDIOMEGALY; CHRONIC DISEASE; DIET; DISEASE MODELS, ANIMAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HEART FAILURE; MYOCARDIAL CONTRACTION; OVARIECTOMY; PHYTOESTROGENS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VENAE CAVAE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 38149023969     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00281.2007     Document Type: Article

References (50)

1. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595, 1987.
2. Bae S, Zhang L. Gender differences in cardioprotection against ischemia/reperfusion injury in adult rat hearts: focus on Akt and protein kinase C signaling. J Pharmacol Exp Ther 315: 1125-1135, 2005.
3. Barrett-Connor E, Stuenkel C. Hormones and heart disease in women: Heart and Estrogen/Progestin Replacement Study in perspective. J Clin Endocrinol Metab 84: 1848-1853, 1999.
4. Baumgarten G, Knuefermann P, Kalra D, Gao F, Taffet GE, Michael L, Blackshear PJ, Carballo E, Sivasubramanian N, Mann DL. Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation 105: 2192-2197, 2002.
5. Beaglehole R. International trends in coronary heart disease mortality and incidence rates. J Cardiovasc Risk 6: 63-68, 1999.
6. Beer S, Reincke M, Kral M, Callies F, Stromer H, Dienesch C, Steinhauer S, Ertl G, Allolio B, Neubauer S. High-dose 17β-estradiol treatment prevents development of heart failure postmyocardial infarction in the rat. Basic Res Cardiol 102: 9-18, 2007.
7. Borras C, Gambini J, Gomez-Cabrera MC, Sastre J, Pallardo FV, Mann GE, Vina J. Genistein, a soy isoflavone, up-regulates expression of antioxidant genes: involvement of estrogen receptors, ERK1/2, and NF-κB. FASEB J 20: 2136-2138, 2006.
8. Brower GL, Gardner JD, Janicki JS. Gender mediated cardiac protection from adverse ventricular remodeling is abolished by ovariectomy. Mol Cell Biochem 251: 89-95, 2003.
9. Brower GL, Janicki JS. Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol 280: H674-H683, 2001.
10. Camper-Kirby D, Welch S, Walker A, Shiraishi I, Setchell KD, Schaefer E, Kajstura J, Anversa P, Sussman MA. Myocardial Akt activation and gender: increased nuclear activity in females vs. males. Circ Res 88: 1020-1027, 2001.
11. Cassidy A. Potential risks and benefits of phytoestrogen-rich diets. Int J Vitam Nutr Res 73: 120-126, 2003.
12. Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 105: 1983-1988, 2002.
13. Chancey AL, Gardner JD, Murray DB, Brower GL, Janicki JS. Modulation of cardiac mast cell-mediated extracellular matrix degradation by estrogen. Am J Physiol Heart Circ Physiol 289: H316-H321, 2005.
14. De Kleijn MJ, Van Der Schouw YT, Wilson PW, Adlercreutz H, Mazur W, Grobbee DE, Jacques PF. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham study (1-4). J Nutr 131: 1826-1832, 2001.
15. Erdman JW Jr. AHA Science Advisory. Soy protein and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation 102: 2555-2559, 2000.
16. Gardner JD, Brower GL, Janicki JS. Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail 8: 101-107, 2002.
17. Gardner JD, Brower GL, Janicki JS. Effects of dietary phytoestrogens on cardiac remodeling secondary to chronic volume overload in female rats. J Appl Physiol 99: 1378-1383, 2005.
18. Gorodeski GI. Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in women. Exp Gerontol 29: 357-375, 1994.
19. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 288: 49-57, 2002.
20. Harris HA. Estrogen receptor-β: recent lessons from in vivo studies. Mol Endocrinol 21: 1-13, 2007.
21. Hayward CS, Kelly RP, Collins P. The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res 46: 28-49, 2000.
22. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613, 1998.
23. Janicki JS, Brower GL, Gardner JD, Chancey AL, Stewart JA Jr. The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev 9: 33-42, 2004.
24. Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. Steroids 55: 330-352, 1990.
25. Kousidou OC, Mitropoulou TN, Roussidis AE, Kletsas D, Theocharis AD, Karamanos NK. Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int J Oncol 26: 1101-1109, 2005.
26. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, Van der Saag PT, van der BB, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139: 4252-4263, 1998.
27. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation 94: 2221-2227, 1996.
28. Li Y, Che M, Bhagat S, Ellis KL, Kucuk O, Doerge DR, Abrams J, Cher ML, Sarkar FH. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 6: 354-363, 2004.
29. Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF, Lin JK. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20: 1945-1952, 1999.
30. Liu Z, Hilbelink DR, Gerdes AM. Regional changes in hemodynamics and cardiac myocyte size in rats with aortocaval fistulas. 2. Long-term effects. Circ Res 69: 59-65, 1991.
31. Machens K, Schmidt-Gollwitzer K. Issues to debate on the Women's Health Initiative (WHI) study hormone replacement therapy: an epidemiological dilemma? Hum Reprod 18: 1992-1999, 2003.
32. Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. Circulation 104: 2256-2259, 2001.
33. Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr 70: 439S-450S, 1999.
34. Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, Schenck-Gustafsson K, Smith SC Jr, Taubert KA, Wenger NK. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 104: 499-503, 2001.
35. Motulsky HJ. Intuitive Biostatistics. New York: Oxford Univ. Press, 1995.
36. Oparil S, Levine RL, Chen SJ, Durand J, Chen YF. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation 95: 1301-1307, 1997.
37. Otsuki M, Dahlman-Wright K, Gustafsson JA. Cardiovascular roles of estrogen receptors: insights gained from knockout models. Nucl Recept Signal 1: e003, 2003.
38. Paradkar PN, Blum PS, Berhow MA, Baumann H, Kuo SM. Dietary isoflavones suppress endotoxin-induced inflammatory reaction in liver and intestine. Cancer Lett 215: 21-28, 2004.
39. Patten RD, Pourati I, Aronovitz MJ, Baur J, Celestin F, Chen X, Michael A, Haq S, Nuedling S, Grohe C, Force T, Mendelsohn ME, Karas RH. 17β-Estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phosphoinositide-3 kinase/Akt signaling. Circ Res 95: 692-699, 2004.
40. Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, de Ziegler D, Collins P. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 36: 2154-2159, 2000.
41. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002.
42. Souzeau E, Belanger S, Picard S, Deschepper CF. Dietary isoflavones during pregnancy and lactation provide cardioprotection to offspring rats in adulthood. Am J Physiol Heart Circ Physiol 289: H715-H721, 2005.
43. Suga H, Sagawa K, Shoukas AA. Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circ Res 32: 314-322, 1973.
44. Thorburn J, Thorburn A. The tyrosine kinase inhibitor, genistein, prevents alpha-adrenergic-induced cardiac muscle cell hypertrophy by inhibiting activation of the Ras-MAP kinase signaling pathway. Biochem Biophys Res Commun 202: 1586-1591, 1994.
45. Tissier R, Waintraub X, Couvreur N, Gervais M, Bruneval P, Mandet C, Zini R, Enriquez B, Berdeaux A, Ghaleh B. Pharmacological postconditioning with the phytoestrogen genistein. J Mol Cell Cardiol 42: 79-87, 2007.
46. Van Der Schouw YT, Kreijkamp-Kaspers S, Peeters PH, Keinan-Boker L, Rimm EB, Grobbee DE. Prospective study on usual dietary phytoestrogen intake and cardiovascular disease risk in Western women. Circulation 111: 465-471, 2005.
47. Williams JK, Adams MR. Estrogens, progestins and coronary artery reactivity. Nat Med 3: 273-274, 1997.
48. Xu Y, Arenas IA, Armstrong SJ, Davidge ST. Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc Res 57: 388-394, 2003.
49. Yan C, Han R. Effects of genistein on invasion and matrix metalloproteinase activities of HT1080 human fibrosarcoma cells. Chin Med Sci J 14: 129-133, 1999.
50. Zhai P, Eurell TE, Cotthaus RP, Jeffery EH, Bahr JM, Gross DR. Effects of dietary phytoestrogen on global myocardial ischemia-reperfusion injury in isolated female rat hearts. Am J Physiol Heart Circ Physiol 281: H1223-H1232, 2001.